It is a broadly described annual report of GlaxoSmithKline Bangladesh Limited in the year of 2014. During the year 2014 GlaxoSmithKline Bangladesh Limited contributed to the government exchequer a sum of Tk. Tk.2,356 million, which is a 21% increase over the previous year (2013: Tk.1,950 million). Net Sales of the Company was Tk 7,187mn, against Tk 6,774mn of last year. This represents a 6% growth over last year. For the year 2014, the Turnover of the Company was Tk 7,187mn, 6% higher than last year. With improvements in cost and restricted spending in marketing, the operating profit (after tax) was at Tk 826mn (51% increase over last year). As a result EPS (Earnings per Share) has increased to Tk 68.63 from Tk 45.35 in 2013. The Consumer Healthcare business of the Company grew by 7%, maintaining a dominant Market Share of 88% in the Health Food Drink category. During the year, the Company has paid a total of Tk 80,000 as Board meeting attendance fees.
The Board of Directors recommended a final dividend of 420% i.e Tk 42 per share of Tk 10.00 each for the year 2014. The recommended dividend, if approved by the shareholders at the Annual General Meeting, will involve a cash outflow of Tk 505.95mn. This year, the Chittagong site successfully achieved 3 STAR rating in the recent A&A audit by EHS (Environment, Health, and Safety) and PQ (Product Quality) auditors. Operational compliance in terms of meeting Global Engineering Standards (GES) and FM Global assessment and TP 13 engineering audits outcome gives us the confidence of controlled operations of the site.
More annual report of GlaxoSmithKline Bangladesh Limited: